# Non-alcoholic Fatty Liver Disease trials: 146 new

Updated November 6, 2026.

146 clinical studies in Non-alcoholic Fatty Liver Disease were first posted on ClinicalTrials.gov from November 14, 2024 to November 6, 2026; 34 have an industry sponsor and 90 are recruiting or about to. The newest, NCT07922720, was posted on November 6, 2026: Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors (Samsung Medical Center).

## The full list

New Non-alcoholic Fatty Liver Disease clinical trials: 146 rows for $7.30, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 6 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/non-alcoholic-fatty-liver-disease

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 146
- Industry sponsored: 34
- Recruiting or not yet: 90
- Latest posted: November 6, 2026

## Newest trials

The newest 100 of 146, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07922720 | Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors | Samsung Medical Center | Not applicable | Not yet recruiting | Hepatic Steatosis, Fatty Liver, Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatotic Liver... | 40 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922720) |
| November 4, 2026 | NCT07915596 | Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Observational | Completed | Type 2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease | 792 | Bangladesh | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915596) |
| October 28, 2026 | NCT07900100 | Evaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients. | Tanta University | Phase 2/3 | Not yet recruiting | NAFLD (Nonalcoholic Fatty Liver Disease) | 60 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900100) |
| October 28, 2026 | NCT07900087 | Evaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease Patients | Tanta University | Phase 2/3 | Not yet recruiting | NAFLD (Nonalcoholic Fatty Liver Disease) | 60 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900087) |
| October 21, 2026 | NCT07884903 | Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks | Shanxi Bethune Hospital | Observational | Not yet recruiting | Obesity & Overweight, Diabetes Mellitus, Type 2, Hypertension, Non-alcoholic Fatty Liver Disease (MASLD)... | 25,974 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884903) |
| October 19, 2026 | NCT07881796 | Effect of Dapagliflozin on Metabolic Parameters in Patients With Non-Alcoholic Fatty Liver Disease | Shalamar Hospital | Not applicable | Completed | Non-Alcoholic Fatty Liver Disease | 146 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881796) |
| October 14, 2026 | NCT07873229 | DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine | Eccogene | Phase 1 | Not yet recruiting | Steatohepatitis, Nonalcoholic, Osteo Arthritis | 40 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873229) |
| October 6, 2026 | NCT07861594 | Lifestyle, Dietary Patterns, and Cardiometabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Among People Living With... | Assiut University | Observational | Not yet recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections, Non-Alcoholic Fatty Liver Disease... | 250 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861594) |
| October 2, 2026 | NCT07854782 | Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD | 1,500 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07854782) |
| September 22, 2026 | NCT07834905 | Nutritional Indices and Inflammatory Markers in MASLD | Assiut University | Observational | Not yet recruiting | Liver Fibrosis, Malnutrition, Non-Alcoholic Fatty Liver Disease | 180 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07834905) |
| September 22, 2026 | NCT07833514 | Misocholic Tablets for Non-Viral Elevated Liver Enzymes | Hanoi Medical University | Phase 3 | Not yet recruiting | Alcohol-Related Liver Disease, Drug-Induced Liver Injury, Non-alcoholic Fatty Liver Disease | 60 | Vietnam | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833514) |
| September 22, 2026 | NCT07832994 | Metaboic Syndrome and Fatty Liver in Celiac Disease Females: Reponse to Exercise in Adolescents | Cairo University | Not applicable | Recruiting | Celiac Disease, Metabolic Syndrome, Non Alcoholic Fatty Liver | 40 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832994) |
| September 18, 2026 | NCT07827430 | Impact of Overt and Subclinical Hypothyroidism on Liver Fibrosis in Patients With MASLD | Assiut University | Observational | Not yet recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hypothyroidism, Liver... | 120 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827430) |
| September 17, 2026 | NCT07825467 | Brown Adipose Tissue Activity and NAFLD Progression | Renmin Hospital of Wuhan University | Observational | Completed | Nonalcoholic Fatty Liver Disease | 96 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07825467) |
| September 15, 2026 | NCT07820800 | NMR Metabolomics-Based Risk Assessment and Stratified Digital Health Interventions in Middle-Aged Adults (PREMAP) | University of Eastern Finland | Not applicable | Recruiting | Type 2 Diabetes, Coronary Heart Disease, Myocardial Infarction, Cerebrovascular Disease, Stroke, Chronic Kidney... | 1,400 | Finland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07820800) |
| September 1, 2026 | NCT07797101 | Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis | The Second Affiliated Hospital of Chongqing Medical University | Not applicable | Not yet recruiting | Cirrhosis, Portal Hypertension, Fatty Liver Disease, GLP-1 | 50 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797101) |
| August 28, 2026 | NCT07793279 | Hypothyroidism and Liver Fibrosis Severity in MASLD | Assiut University | Observational | Not yet recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism, Liver Cirrhosis, Non-Alcoholic Fatty Liver... | 85 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793279) |
| August 20, 2026 | NCT07775638 | Detecting Liver Fibrosis in Patients At-risk | Helse Stavanger HF | Observational | Not yet recruiting | Fatty Liver, NAFLD - Non-Alcoholic Fatty Liver Disease, Nash, MASLD (Metabolic Dysfunction-Associated Steatotic Liver... | 1,200 | Norway | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775638) |
| August 17, 2026 | NCT07768956 | Effects of Turkish Coffee and Green Tea in Fatty Liver Disease | Okan University | Not applicable | Completed | Non Alcoholic Fatty Liver Disease | 47 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07768956) |
| August 17, 2026 | NCT07768657 | Improvement in Hepatic Function Through Sumac (Rhus Coriaria L.) Supplement Along With a Calorie-restricted Diet for the Management of... | University of Lahore | Not applicable | Completed | Liver Biomarkers, Lipid Profile, Glucose, Insulin | 102 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07768657) |
| July 31, 2026 | NCT07740109 | The Effects of 5-methyltetrahydrofolate Supplementation in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease | Tabriz University of Medical Sciences | Not applicable | Not yet recruiting | Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated... | 44 | Iran | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07740109) |
| July 28, 2026 | NCT07731360 | Non-Invasive Diagnostic Panel for MASLD in Children With Obesity | Kayseri City Hospital | Observational | Not yet recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease, Pediatric Obesity, Insulin Resistance Syndrome | 180 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07731360) |
| July 28, 2026 | NCT07730905 | Analysis of Renal Impairment Characteristics and High-Risk Factors in Chronic Hepatitis B Patients on Long-Term Oral Nucleos(t)Ide Analogues | Foshan Hospital of Traditional Chinese Medicine | Observational | Completed | Non-alcoholic Fatty Liver Disease, Renal Function Impairment | 300 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730905) |
| July 24, 2026 | NCT07726368 | Study of ECC4703 With Sulfasalazine and Pitavastatin | Eccogene | Phase 1 | Recruiting | Non-alcoholic Fatty Liver Disease (NAFLD), Dyslipidaemia | 40 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07726368) |
| July 21, 2026 | NCT07716384 | Wearable Patch Ultrasound Probe for Diagnosis of Liver Stiffness | Second Affiliated Hospital of Xi'an Jiaotong University | Observational | Not yet recruiting | Liver Fibrosis, Liver Cirrhosis, NAFLD (Nonalcoholic Fatty Liver Disease), HEPATITIS B CHRONIC | 150 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07716384) |
| July 20, 2026 | NCT07713992 | Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease... | Tianjin Medical University | Not applicable | Not yet recruiting | Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus | 72 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713992) |
| July 13, 2026 | NCT07697313 | High-intensity Interval Training Versus Moderate Intensity Continuous Training on Gut Microbiota in Non-alcoholic Fatty Liver | Horus University | Not applicable | Not yet recruiting | Non-alcoholic Fatty Liver | 60 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07697313) |
| July 9, 2026 | NCT07693777 | A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia | Zhejiang Doer Biologics Co., Ltd. | Phase 3 | Not yet recruiting | Severe Hypertriglyceridemia (sHTG), Hypertriglyceridemia | 480 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07693777) |
| June 23, 2026 | NCT07662356 | Clinical Course and Biomarkers Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Chinese Patients With Obesity | Chinese University of Hong Kong | Observational | Recruiting | Nonalcoholic Fatty Liver Disease (NAFLD) | 200 | Hong Kong | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662356) |
| June 22, 2026 | NCT07658755 | Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme | Hospital General Universitario Gregorio Marañon | Observational | Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis, Non-alcoholic Fatty Liver Disease NAFLD, Type... | 3,000 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658755) |
| June 12, 2026 | NCT07644936 | Molecular Characterization of Autoimmune Hepatitis: A Lipidomic Approach | Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis | Observational | Not yet recruiting | Autoimmune Hepatitis, Non-Alcoholic Fatty Liver Disease | 24 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07644936) |
| June 9, 2026 | NCT07637006 | Linzhi Jianghuang Fufang Huoxue Anshen Capsule for Non-alcoholic Fatty Liver | Hong Kong Baptist University | Phase 2 | Not yet recruiting | Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | 180 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07637006) |
| June 8, 2026 | NCT07631637 | Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Regeneron Pharmaceuticals | Phase 2 | Recruiting | Metabolic Dysfunction-Associated Steatohepatitis, MASH | 360 | Puerto Rico, United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631637) |
| June 3, 2026 | NCT07622680 | Comparative Effects of Mediterranean and DASH Diet on Hepatic Function | University of Lahore | Not applicable | Completed | NAFLD (Nonalcoholic Fatty Liver Disease), Hep A | 75 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07622680) |
| May 20, 2026 | NCT07599241 | Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues | Cairo University | Not applicable | Recruiting | Subclinical hypothyroïdism, Non-Alcoholic Fatty Liver Disease, Primary Open Angle Glaucoma | 40 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07599241) |
| May 12, 2026 | NCT07581951 | A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH | Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | Recruiting | MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH (Non-Alcoholic Steatohepatitis) | 886 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581951) |
| May 12, 2026 | NCT07580482 | The Referral to Hepatology Can be Improved Through an Electronic Medical Record (EMR)-Based Best Practice Alert (BPA) for an Appropriate... | University of Kansas Medical Center | Not applicable | Completed | Liver Diseases, Liver Fat, Diabetes Mellitus, Type 2, Non-Alcoholic Steatohepatitis | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07580482) |
| May 6, 2026 | NCT07570810 | Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM | Shanghai Jiao Tong University School of Medicine | Not applicable | Not yet recruiting | Type 2 Diabetes, Obesity, Non-alcoholic Fatty Liver Disease | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07570810) |
| May 4, 2026 | NCT07564947 | Impact of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease (GL-MAFLD-NRF2 Study) | University of Agriculture, Peshawar | Not applicable | Enrolling by invitation | MAFLD, Fatty Liver, Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD, Fatty Liver, Nonalcoholic, Fatty Liver... | 40 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07564947) |
| April 28, 2026 | NCT07553663 | Evaluating the Pharmacokinetics and Safety of Miricorilant | Corcept Therapeutics | Phase 1 | Completed | Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic... | 14 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07553663) |
| April 14, 2026 | NCT07527910 | A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD | Regeneron Pharmaceuticals | Phase 2 | Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 204 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527910) |
| April 9, 2026 | NCT07518784 | Accurate Point of Care Liver Disease Diagnostics (Phase 2) | University of California, San Diego | Observational | Completed | MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), NAFLD, NAFLD (Nonalcoholic Fatty Liver Disease) | 26 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07518784) |
| April 7, 2026 | NCT07514377 | JiGenerations Health Cohort Study：Parental Exposure and Intergenerational Health in China | National Research Institute for Family Planning, China | Observational | Active not recruiting | Environmental Exposure, Fertility, Health Problems in Pregnancy, Adverse Pregnancy Outcomes, Birth Defects, Child... | 100,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07514377) |
| March 27, 2026 | NCT07497750 | Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver Disease - A... | University Hospital, Toulouse | Not applicable | Not yet recruiting | Non Alcoholic Fatty Liver Disease | 216 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07497750) |
| March 27, 2026 | NCT07493967 | Short and Long Term Clinical and Patient-Reported Outcomes Associated With Intragastric Balloon Placement in Patients With Nonalcoholic... | Methodist Health System | Observational | Enrolling by invitation | NAFLD | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493967) |
| March 19, 2026 | NCT07481734 | Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) | Hudson Biotech | Phase 2 | Recruiting | Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07481734) |
| February 12, 2026 | NCT07407634 | A Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects. | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Early phase 1 | Not yet recruiting | Non-Alcoholic Fatty Liver Disease | 94 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407634) |
| February 11, 2026 | NCT07403604 | Effect of Insulin Lowering on Lipogenesis | Columbia University | Phase 1 | Recruiting | Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity | 25 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07403604) |
| January 30, 2026 | NCT07378280 | Study to Investigate the Effect of L. Lactis CKDB001 Administration on Liver Aminotransferases in Subjects With NAFLD | Chuncheon Sacred Heart Hospital | Not applicable | Completed | Non Alcoholic Fatty Liver Disease | 95 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07378280) |
| January 29, 2026 | NCT07376486 | Duodenal pulsENDO as an Early Treatment for Type 2 DM | Chinese University of Hong Kong | Not applicable | Recruiting | Diabete Mellitus, T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin) | 40 | Hong Kong | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07376486) |
| January 26, 2026 | NCT07366710 | Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET | Copenhagen University Hospital, Rigshospitalet | Not applicable | Active not recruiting | Glucose Metabolism, NAFLD (Nonalcoholic Fatty Liver Disease) | 36 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07366710) |
| January 23, 2026 | NCT07363707 | A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes. | Beni-Suef University | Phase 4 | Completed | NAFLD (Nonalcoholic Fatty Liver Disease) | 108 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07363707) |
| January 22, 2026 | NCT07358546 | A Study of Efimosfermin Alfa in Adults With Hepatic Impairment | GlaxoSmithKline | Phase 1 | Recruiting | Non-alcoholic Fatty Liver Disease | 32 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07358546) |
| January 13, 2026 | NCT07338331 | Comparative Effects of Aspirin, Metformin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic... | Galala University | Not applicable | Completed | Diabete Type 2, Non Alcoholic Fatty Liver | 80 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07338331) |
| January 13, 2026 | NCT07336563 | ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study | Jarosław Drobnik | Observational | Not yet recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH), Metabolic... | 10,000 | Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07336563) |
| January 13, 2026 | NCT07335198 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to... | GlaxoSmithKline | Phase 1 | Completed | Non-alcoholic Fatty Liver Disease | 30 | New Zealand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07335198) |
| January 7, 2026 | NCT07321925 | Thermoacoustic Method for Estimating Liver Fat Fraction | Endra Lifesciences | Observational | Recruiting | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated... | 49 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07321925) |
| December 30, 2025 | NCT07310407 | Rutin and Vitamin C in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) | Ain Shams University | Phase 2 | Not yet recruiting | NAFLD | 120 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07310407) |
| December 29, 2025 | NCT07308548 | A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH ) | Hinova Pharmaceuticals Inc. | Phase 2 | Recruiting | NAFLD (Non-alcoholic Fatty Liver Disease) | 80 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07308548) |
| December 19, 2025 | NCT07294963 | Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease | Khyber Medical University Peshawar | Not applicable | Completed | Non-Alcoholic Fatty Liver Disease, Neurocognitive Disorders | 45 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07294963) |
| December 17, 2025 | NCT07288138 | A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and... | Eccogene | Phase 2 | Recruiting | Metabolic Dysfunction-associated Steatohepatitis | 160 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07288138) |
| December 8, 2025 | NCT07270601 | Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis | ContextVision AB | Not applicable | Recruiting | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD - Non-Alcoholic Fatty Liver Disease | 110 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07270601) |
| December 8, 2025 | NCT07269197 | Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes | Josip Juraj Strossmayer University of Osijek | Observational | Completed | Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2 | 67 | Croatia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07269197) |
| December 8, 2025 | NCT07268937 | Assessment of Hepatic Steatosis Using Dedicated Software Implemented on Ultrasound Devices | Fondazione IRCCS Policlinico San Matteo di Pavia | Observational | Completed | Non-alcoholic Fatty Liver Disease (NAFLD) | 25 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07268937) |
| December 4, 2025 | NCT07265297 | Using Hydroxychloroquine (HCQ) to Treat Steatohepatitis | National Taiwan University Hospital | Phase 3 | Recruiting | Steatohepatitis, Nonalcoholic | 210 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07265297) |
| December 4, 2025 | NCT07265011 | Ultrasound-Based Estimation of Hepatic Steatosis in Pediatric MASLD | Jae Won Choi | Not applicable | Completed | MASLD, Pediatric | 50 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07265011) |
| December 1, 2025 | NCT07255781 | Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy | University of California, San Diego | Observational | Withdrawn | Psoriasis (PsO), PsA (Psoriatic Arthritis), NAFLD (Nonalcoholic Fatty Liver Disease) | 0 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07255781) |
| November 25, 2025 | NCT07248371 | Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases | Chang Gung Memorial Hospital | Observational | Recruiting | Metabolic Syndrome (MetS), Obesity & Overweight, Cardiovascular Diseases (CVD), Chronic Kidney Disease, Nonalcoholic... | 6,266 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07248371) |
| November 21, 2025 | NCT07241195 | A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic... | The Affiliated Hospital of Hangzhou Normal University | Observational | Recruiting | NAFLD and NASH, NAFLD( Non-alcoholic Fatty Liver Disease ), NAFLD Cirrhosis | 20,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07241195) |
| November 20, 2025 | NCT07237750 | iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) +Optimized Lifestyle Intervention (OLI) vs Sham + OLI for Weight Loss | Liu Yan | Not applicable | Recruiting | Overweight and/or Obesity, Metabolic Syndrome, Nonalcoholic Fatty Liver Disease | 216 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07237750) |
| October 27, 2025 | NCT07221227 | A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH | GlaxoSmithKline | Phase 3 | Recruiting | Non-alcoholic Fatty Liver Disease | 1,200 | Australia, Canada, Hong Kong, Japan, New Zealand, Puerto Rico, Saudi Arabia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221227) |
| October 27, 2025 | NCT07221188 | A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or... | GlaxoSmithKline | Phase 3 | Recruiting | Non-alcoholic Fatty Liver Disease | 1,250 | Australia, France, Germany, Hong Kong, Japan, New Zealand, Saudi Arabia, United... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221188) |
| October 9, 2025 | NCT07214870 | A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat | Novo Nordisk A/S | Phase 1 | Active not recruiting | Fatty Liver Disease | 29 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07214870) |
| October 1, 2025 | NCT07200934 | Effect of Adding TENS to Mediterranean Diet on Appetite and Liver Enzymes in Nonalcoholic Fatty Liver Patients | Cairo University | Not applicable | Completed | Nonalcoholic Fatty Liver | 50 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07200934) |
| September 30, 2025 | NCT07198516 | The Improvement Effect of Henggliejin on Fatty Liver in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver: | Fujian Medical University Union Hospital | Early phase 1 | Not yet recruiting | NAFLD, Diabete Type 2 | 149 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07198516) |
| September 26, 2025 | NCT07193927 | Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A... | AB Biotics, SA | Phase 2 | Recruiting | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver Disease, Nonalcoholic, Overweight (BMI... | 60 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07193927) |
| September 19, 2025 | NCT07182136 | The Impact of Hepatic Steatosis on Survival After Pancreaticoduodenectomy | Wei-Hsun Lu | Observational | Completed | Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy | 200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07182136) |
| September 18, 2025 | NCT07180745 | Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease | Badr University | Phase 4 | Not yet recruiting | Non-alcoholic Fatty Liver Disease NAFLD, Non-alcoholic Steatohepatitis NASH | 400 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07180745) |
| September 15, 2025 | NCT07172997 | Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers | Royal College of Surgeons in Ireland - Medical University of Bahrain | Observational | Active not recruiting | MASLD, T2DM (Type 2 Diabetes Mellitus), Non-alcoholic Fatty Liver Disease (NAFLD), Obesity | 163 | Bahrain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07172997) |
| September 11, 2025 | NCT07168551 | Is There a Relationship Between Uric Acid Level and Liver Fibrosis in Obese Patients | Assiut University | Observational | Not yet recruiting | Hyperuricemia, NAFLD (Nonalcoholic Fatty Liver Disease), Liver Fibrosis | 111 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07168551) |
| September 10, 2025 | NCT07165028 | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Eli Lilly and Company | Phase 3 | Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease | 4,500 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07165028) |
| September 2, 2025 | NCT07149571 | To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in... | Tongji Hospital | Observational | Recruiting | Nonalcoholic Fatty Liver Disease, Metabolic-associated Fatty Liver Disease | 500 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07149571) |
| August 28, 2025 | NCT07146815 | PolyCystic Ovary Syndrome as Suggested Risk Group for Non-Alcoholic Fatty Liver Disease | Ziekenhuis Oost-Limburg | Not applicable | Completed | NAFLD (Nonalcoholic Fatty Liver Disease), Polycystic Ovarian Syndrome (PCOS) | 157 | Belgium | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07146815) |
| August 19, 2025 | NCT07130318 | Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise | Cairo University | Not applicable | Recruiting | Familial Mediterranean Fever, Non-Alcoholic Fatty Liver Disease | 40 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07130318) |
| August 19, 2025 | NCT07128797 | a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic... | Tasly Biopharmaceuticals Co., Ltd. | Phase 1 | Recruiting | NAFLD (Non-alcoholic Fatty Liver Disease), NASH (Nonalcoholic Steatohepatitis) | 32 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07128797) |
| August 5, 2025 | NCT07104786 | Comparison of Effectiveness of Obeticholic Acid With Vitamin E in Patients of Non-alcoholic Fatty Liver Disease | King Edward Medical University | Phase 2 | Completed | Non Alcoholic Fatty Liver Disease | 90 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07104786) |
| August 5, 2025 | NCT07103603 | MHT and Liver Function in Postmenopausal Women | Ipek B. Ozcivit Erkan, MD | Not applicable | Completed | Menopause, Non Alcholic Fatty Liver Disease, Hepatic Steatosis | 44 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07103603) |
| August 1, 2025 | NCT07099118 | A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Recruiting | Non - Alcoholic Steatohepatitis | 96 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07099118) |
| July 30, 2025 | NCT07093346 | The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic... | University of Nottingham | Not applicable | Recruiting | Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated... | 45 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07093346) |
| July 25, 2025 | NCT07086989 | Cardiovascular Risk in Children With Chronic Conditions Study | Semmelweis University | Observational | Recruiting | Kidney Transplant, Familial Hypercholesterolaemia, Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM)... | 300 | Hungary | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07086989) |
| July 17, 2025 | NCT07070362 | Digital Early Warning System for Acute Lung Injury in Liver Surgery | Beijing Tsinghua Chang Gung Hospital | Observational | Recruiting | Acute Lung Injury(ALI), Liver Cirrhosis, ARDS, Human, MASLD, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic... | 3,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07070362) |
| July 16, 2025 | NCT07068191 | Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly | Phenomen Pharma | Not applicable | Recruiting | Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL)... | 90 | Russia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07068191) |
| July 4, 2025 | NCT07051863 | Prospective Cohort and Biobank of Patients With Nonalcoholic Fatty Liver Disease | Fondazione Epatocentro Ticino | Observational | Recruiting | NAFLD, MASH, NASH/MASH | 300 | Switzerland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07051863) |
| June 18, 2025 | NCT07027332 | Liver Stiffness And Steatosis Assessment In Women With Polycystic Ovary Syndrome Using Fibroscan | Bezmialem Vakif University | Observational | Completed | Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease | 36 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07027332) |
| June 17, 2025 | NCT07024212 | Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects | Zhejiang Doer Biologics Co., Ltd. | Phase 2 | Active not recruiting | MASLD | 110 | China, Hong Kong | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07024212) |
| June 15, 2025 | NCT07021443 | The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical Setting | Universitair Ziekenhuis Brussel | Observational | Completed | Non-Alcoholic Fatty Liver Disease | 50 | Belgium | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07021443) |
| June 13, 2025 | NCT07020377 | Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM). | Amira Bisher,PhD | Phase 1/2 | Active not recruiting | Diabetes Mellitus, Non Alcholic Fatty Liver Disease | 60 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020377) |
| June 6, 2025 | NCT07007741 | Digital Therapy for Fatty Liver Disease | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Not applicable | Active not recruiting | Steatohepatitis, Nonalcoholic, Nonalcoholic Fatty Liver | 141 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07007741) |
| May 21, 2025 | NCT06982378 | GLP-1 RA on Liver OMICS in MASLD | Medical College of Wisconsin | Observational | Withdrawn | NAFLD, Diabetes, Obesity | 0 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06982378) |
| May 16, 2025 | NCT06975579 | The COherence of Scatter Identification and Exclusion Algorithm Study | Institute of Cancer Research, United Kingdom | Observational | Recruiting | Steatohepatitis, Nonalcoholic | 15 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06975579) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Assiut University | 8 | October 6, 2026 |
| Cairo University | 6 | September 22, 2026 |
| GlaxoSmithKline | 5 | January 22, 2026 |
| Regeneron Pharmaceuticals | 4 | October 2, 2026 |
| Tanta University | 3 | October 28, 2026 |
| Eccogene | 3 | October 14, 2026 |
| University of Lahore | 2 | August 17, 2026 |
| Zhejiang Doer Biologics Co., Ltd. | 2 | July 9, 2026 |
| Chinese University of Hong Kong | 2 | June 23, 2026 |
| Corcept Therapeutics | 2 | April 28, 2026 |
| University of California, San Diego | 2 | April 9, 2026 |
| Ain Shams University | 2 | December 30, 2025 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2 | March 21, 2025 |
| Federal State Budgetary Scientific Institution | 2 | December 10, 2024 |
| Samsung Medical Center | 1 | November 6, 2026 |
| Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 1 | November 4, 2026 |
| Shanxi Bethune Hospital | 1 | October 21, 2026 |
| Shalamar Hospital | 1 | October 19, 2026 |
| Hanoi Medical University | 1 | September 22, 2026 |
| Renmin Hospital of Wuhan University | 1 | September 17, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 51 | November 6, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 50 | November 4, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 14 | October 14, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 12 | June 9, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 9 | October 2, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 4 | January 23, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 2 | October 28, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 2 | February 12, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 2 | June 13, 2025 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 27 | October 21, 2026 |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 21 | October 2, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 16 | October 28, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 8 | June 8, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 7 | June 12, 2026 |
| [Pakistan](https://specstream.ai/data/clinical-trials/country/pakistan) | 6 | October 19, 2026 |
| [Hong Kong](https://specstream.ai/data/clinical-trials/country/hong-kong) | 6 | June 23, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 5 | October 14, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 5 | August 17, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 5 | June 22, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 5 | October 27, 2025 |
| [New Zealand](https://specstream.ai/data/clinical-trials/country/new-zealand) | 4 | January 13, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 4 | December 4, 2025 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 4 | October 27, 2025 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 4 | September 10, 2025 |
| [Puerto Rico](https://specstream.ai/data/clinical-trials/country/puerto-rico) | 3 | June 8, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 3 | March 27, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 3 | January 30, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 3 | October 27, 2025 |
| [Switzerland](https://specstream.ai/data/clinical-trials/country/switzerland) | 3 | September 10, 2025 |
| [Finland](https://specstream.ai/data/clinical-trials/country/finland) | 2 | September 15, 2026 |
| [Norway](https://specstream.ai/data/clinical-trials/country/norway) | 2 | August 20, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 2 | January 26, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 2 | January 13, 2026 |
| [Saudi Arabia](https://specstream.ai/data/clinical-trials/country/saudi-arabia) | 2 | October 27, 2025 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).